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Abstract Staphylococcus aureus has been an important
human pathogen throughout history and is currently a
leading cause of bacterial infections worldwide. S. aureus
has the unique ability to cause a continuum of diseases,
ranging from minor skin infections to fatal necrotizing
pneumonia. Moreover, the emergence of highly virulent,
drug-resistant strains such as methicillin-resistant S. aureus
in both healthcare and community settings is a major
therapeutic concern. Neutrophils are the most prominent
cellular component of the innate immune system and
provide an essential primary defense against bacterial
pathogens such as S. aureus. Neutrophils are rapidly
recruited to sites of infection where they bind and ingest
invading S. aureus, and this process triggers potent
oxidative and non-oxidative antimicrobial killing mecha-
nisms that serve to limit pathogen survival and dissemina-
tion. S. aureus has evolved numerous mechanisms to evade
host defense strategies employed by neutrophils, including
the ability to modulate normal neutrophil turnover, a
process critical to the resolution of acute inflammation.
Here we provide an overview of the role of neutrophils in
host defense against bacterial pathogens and discuss
strategies employed by S. aureus to circumvent neutrophil
function.
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Introduction
Staphylococcus aureus has been a serious threat to human
health throughout history and was one of the first bacterial
pathogens to be identified. It was the ability of S. aureus to
cause disease that led to its first description in human pus
over 130 years ago by Sir Alexander Ogston [1, 2]. Since
then, S. aureus has proven itself well adapted for interaction
with humans and is currently a leading cause of human
bacterial disease worldwide [3]. For example, S. aureus has
been reported as the leading cause of bacterial infections
involving bloodstream, lower respiratory tract, and skin and
soft tissue in many industrialized countries including the
United States, Canada, Europe, Latin America, and the
Western Pacific [3]. S. aureus is also the most abundant
cause of hospital-associated infections in the United States
[4–6]. Correspondingly, this large number of infections
creates a significant financial burden, making detrimental
impacts on public health systems around the world [6].
With approximately half a million people acquiring
staphylococcal infections in the USA per year, the cost of
S. aureus healthcare-associated infections was estimated to
exceed 14 billion dollars in 2003 [7, 8]. Interestingly, this
versatile pathogen is considered a human commensal
microbe, as it asymptomatically colonizes the anterior nares
of ∼30% of non-institutionalized individuals [9]. Yet given
the opportunity, S. aureus has the unique ability to cause a
wide range of infections and syndromes, including skin and
soft tissue infections, food borne illness, toxic shock
syndrome, bacteremia, sepsis, endocarditis, osteomyelitis,
necrotizing fasciitis, and pneumonia. An armament of
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to immune evasion molecules, lends S. aureus effective at
causing disease [10]. In addition, the rise in occurrence and
severity of infections over the last 70 years has been
attributed to the evolution of highly virulent, drug-resistant
strains that now challenge our ability to treat such
infections. Further, there has been a recent increase in the
burden of antibiotic-resistant S. aureus within the commu-
nity setting [11, 12]. These community-associated
methicillin-resistant S. aureus (CA-MRSA) strains have an
enhanced virulence potential, in that they are able to cause a
wide range of disease in otherwise healthy individuals,
drastically changing previous clinical epidemiology of
methicillin-resistant S. aureus (MRSA) [13]. The enhanced
virulence potential is related in part to the ability of these
strains to circumvent killing by human polymorphonuclear
leukocytes (PMNs or neutrophils), the most prominent
cellular host defense against invading microorganisms.
This article will provide a brief history of the rise of
highly-virulent, drug-resistant S. aureus strains, an over-
view of the role of neutrophils in host defense, and review
immune evasion strategies employed by S. aureus to
circumvent neutrophil function, including strategies yielding
the enhanced virulence of CA-MRSA strains.
S. aureus and antibiotics: a brief history
S. aureus is notoriously adept at acquiring resistance to
antibiotics, owing to much of the pathogen’s recent success
[11, 14]. Inasmuch as the development and widespread
clinical use of penicillin in the early 1940s marked the
beginning of the “antibiotic era,” reports of S. aureus strains
harboring resistance to penicillin by 1942 marked the
beginning of our critical, ongoing battle against antibiotic
resistance [15]. Thereafter, the prevalence of penicillin-
resistant S. aureus (PRSA) increased dramatically in noso-
comial settings, with the increase being attributed completely
to the use of penicillin [16–18]. Increases in the number of
PRSA infections lead to the inefficacy of penicillin treatment
within 10 years of the miracle drug’s introduction, necessi-
tating the development of alternative treatments [17, 19].
Likewise, the introduction of methicillin—a β-lactam anti-
biotic developed for treatment of PRSA infections—in 1959
quickly led to the onset of a second “epidemic wave” of
antibiotic resistance, as infections caused by methicillin-
resistant strains were reported 2 years later in 1961 [17, 20,
21]. Thereafter, MRSA became endemic to hospitals and
health care facilities worldwide, leading to the global MRSA
pandemic in health care settings that continues today [3, 17,
22]. A high percentage of hospital-associated S. aureus
infections in the USA are caused by MRSA [7, 23, 24].
Notably, invasive MRSA infections are considered a
major cause of human mortality in the USA—there were
approximately 19,000 deaths in the USA in 2005 and the
mortality rate for invasive MRSA infections was reported
as 20% [5]. In the USA, MRSA is likely the leading cause
of death by any single infectious agent, with fatalities
from MRSA infection estimated to surpass those caused
by HIV/AIDS [5, 25]. Antibiotic use within the nosoco-
mial setting has created high selective pressure for
development of antibiotic resistance, and S. aureus has
acquired resistance to virtually all antibiotics [14, 26].
Multidrug-resistant MRSA strains, which combine resis-
tance to β-lactam antibiotics with resistance to other
classes of antibiotics, are becoming increasingly frequent
in the healthcare setting, representing a major concern for
treatment of MRSA infections [11]. Taken together, the
high occurrence of infections caused by drug-resistant S.
aureus is problematic and demonstrates the urgent need
for development of novel treatment strategies.
Rise of community-associated MRSA
The majority of infections caused by MRSA have histor-
ically been hospital-associated, occurring in immunocom-
promised individuals or in patients with pre-disposing risk
factors, such as surgery, surgical incisions, the presence of
indwelling medical devices, or pre-existing infections [6,
27–29]. However, MRSA epidemiology changed in the
1990s with reports of infections caused by strains of MRSA
occurring outside of the healthcare setting in otherwise
healthy individuals, the first reports of bona fide CA-
MRSA infections [12, 29]. CA-MRSA also spread rapidly
among diverse groups of healthy individuals, demonstrating
an enhanced transmissibility and/or ability to colonize, in
addition to being highly virulent [11, 18, 30–41]. CA-
MRSA infections have been reported in regions all over the
world, including Asia, Australia, Canada, Europe, South
America, and the USA, rapidly reaching pandemic propor-
tions [42–51]. The epidemic spread of CA-MRSA in the
USA has led to an overall increase in the burden of MRSA
[52]. Concomitant increases in staphylococcal burden have
been observed worldwide since the emergence of CA-
MRSA [51, 53–55]. The majority of infections caused by
CA-MRSA present as skin and soft tissue infections
(∼90%) and most are abscesses or cellulitis with purulent
drainage [52, 53, 55–57]. However, the most prominent
CA-MRSA strains also have a proven ability to cause
severe invasive diseases such as necrotizing fasciitis and
necrotizing pneumonia, rarely seen before the rise of CA-
MRSA [17, 29, 58–63]. Although invasive infections
associated with CA-MRSA are relatively infrequent, they
accounted for 14% of all invasive MRSA-associated
fatalities in the USA in 2005 [5]. Predominant CA-MRSA
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types USA300 and USA400 are genetically distinct from
traditional HA-MRSA strains in part because they contain a
unique staphylococcal cassette chromosome (SCC) mec
element (SCCmec type IV) [17, 64–68]. In contrast to
larger SCCmec elements that encode resistance to multiple
antibiotics, SCCmec type IV provides resistance to solely
β-lactam antibiotics with apparently little or no fitness cost
to the pathogen, likely contributing to the success of CA-
MRSA strains [17, 64–68]. Other genetic and molecular
factors are associated with the unique ability of CA-MRSA
strains to disseminate rapidly and cause disease in other-
wise healthy individuals. These factors will be discussed in
further detail below.
The ability of S. aureus to cause disease has fueled much
research effort aimed at understanding the intricacies of
interaction between S. aureus and host immune cells. This
has resulted in the description of multiple, redundant
strategies employed by S. aureus to evade and/or combat
host immune response mechanisms. Many of these strate-
gies serve to protect/defend the microbe against primary
interaction with the innate immune response, which
includes interaction with neutrophils. As the major cellular
component of the innate immune system, neutrophils serve
as the critical, primary defense against invading organisms,
providing a rapid, non-specific, and potent response to
infectious challenge. Defects in neutrophil function result in
serious immune deficiencies and syndromes and are
associated with recurrent and often fatal S. aureus disease
[69, 70]. Thus, there is no question that neutrophils are
critical for defense against S. aureus infections. On the
other hand, S. aureus—especially CA-MRSA—have the
demonstrated ability to circumvent killing by human
neutrophils, and can ultimately cause rapid destruction of
these important host cells [71, 72]. This unique ability is
linked to the enhanced virulence of these strains and their
capacity to cause disease [13]. Understanding the complex
interaction between S. aureus and human neutrophils is
critical to understanding the ability of S. aureus to cause
disease.
Neutrophils in the innate immune response
A brief historical perspective
Neutrophils are classically underappreciated professional
phagocytes, with regard to the history and development of
modern immunology. The focus of early immunologists
was aimed at understanding the life-cycles and functions of
lymphocyte sub-types, and their ability to play diverse roles
in antigen presentation, direction and regulation of immune
response, and cytotoxic capacity, all in the context of the
novel concept of adaptive (acquired) immunity. Although
non-specific innate immunity was appreciated, the only
professional phagocytes of noted significance were mono-
nuclear phagocytes—monocytes and macrophages. Unlike
neutrophils, monocytes were known to be long-lived cells
with significant metabolic capacity and the ability to
produce immune regulatory factors. Moreover, they were
well considered for their antigen-presenting capacity as
well as the ability to differentiate into tissue macrophages
and other fixed tissue cell types. The ability of neutrophils
to rapidly migrate to sites of inflammation as well as their
capacity to surround and engulf foreign bodies was
described in the early twentieth century. However, subse-
quent studies demonstrating rapid neutrophil turnover in
blood, short tissue life spans, small capacity for oxidative
phosphorylation, utilization of primarily anaerobic metab-
olism, and little known capacity to synthesize new proteins,
engendered neutrophils largely as end-stage cells with
limited metabolic capacity [73–76].
However, research performed in the late 1960s marked
the first of a large body of evidence that turned the tide for
the underappreciated neutrophil. This work ultimately
evolved into our modern understanding of innate immunity,
which now encompasses the critical, diverse roles of
neutrophils as potent executioners in host defense, and
serve as an important interface between innate and adaptive
immune responses. These early studies demonstrated for
the first time that human neutrophils produce potent
reactive oxygen species and contain antimicrobial proteins
and enzymes in cytosolic organelles known as azurophilic
granules [77–80]. Biochemical studies that continued
through the late 1980s and early 1990s characterized in
detail, additional, important capabilities of neutrophils
including the assembly and activation of the phagocyte
NADPH oxidase, mechanistic functions of granule proteins,
the role of actin in the mobilization of phagocytic cells, and
the discovery that bacterial-derived N-formyl peptides
induce chemotaxis and enhance microbicidal functions of
neutrophils [81–90]. These studies quickly drew additional
interest, sparking the use of neutrophils as model host cells
for the study of new signal transduction pathways that
included calcium transients, phosphorylation events, G
protein-coupled receptors, and phospholipid signaling and
metabolism [91–100]. Further validation of the diversity
and importance of neutrophil function came with the more
recent description of mechanisms underlying normal neu-
trophil turnover, which we now know occurs by spontane-
ous or constitutive apoptosis. The final stage of neutrophil
differentiation can be considered as the induction of
apoptosis, and this process leads to the recognition and
phagocytosis of apoptotic neutrophils by macrophages
[101–104]. In addition, apoptosis or a form of programmed
cell death similar to apoptosis is typically induced by
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removal of spent neutrophils serves to prevent inadvertent
release of tissue-damaging molecules from dying neutro-
phils should they undergo lysis, and thereby promotes
resolution of inflammatory response. [105]. Contrary to the
classic institution, recent studies have clearly demonstrated
a relatively high transcriptional capacity for neutrophils,
with the potential to synthesize many new proteins in
response to various stimuli [106, 107]. This includes the
production of multiple cytokines and chemokines, expand-
ing the diverse function of neutrophils as regulators of
immune function [108]. In corroboration, the importance of
neutrophils was gradually placed in proper perspective with
the description of several serious human diseases caused by
underlying neutropenia and/or defects in neutrophil func-
tion. These conditions are associated with an increased risk
of infection from bacteria and fungi [70]. Additionally,
medically induced neutropenia, e.g., during cancer chemo-
therapy or use of cytotoxic drugs, is the most common
immunodeficiency associated with significant morbidity,
demonstrating in part the relationship between functions
served by neutrophils and the outcome of infection [109–
112]. Collectively, the current body of evidence disputes
the early, naïve concept of the neutrophil, unequivocally
demonstrating the indispensable nature and diverse function
of these cells in the defense against many invading
microorganisms. Ultimately this has redefined the function
and importance of the innate immune system.
Neutrophil development
Neutrophils are short-lived granulocytes derived from
pluripotent hematopoietic stem cells in the bone marrow
[113]. Although granulocytes and lymphocytes are derived
from similar pluripotent stem cells, granulopoiesis is
distinct from that of lymphopoiesis, requiring a unique set
of transcriptional regulators that facilitate the maturation of
granule proteins and surface markers/receptors characteris-
tic of granulocytes [114, 115]. Further distinction of
granulocytes includes morphological characteristics, such
as the presence of a multi-lobed nucleus. The majority of
hematopoiesis is devoted to granulopoiesis, as nearly 60%
of leukocytes within the bone marrow are granulocyte
precursors [73, 75]. Early in the neutrophil differentiation
process, cells develop phagocytic capacity followed by
development of oxygen-dependent microbicidal activity,
increased adhesiveness, cell motility, chemotactic response,
and other cell type-specific traits, proceeding through a
well-characterized, carefully regulated, multi-step progres-
sion into mature neutrophils [113, 114, 116]. During
maturation the number of mitochondria and ribosomes
decreases, while glycogen granules, the main source of
energy, fill the cytoplasm of mature neutrophils [70, 73].
There are two major populations of granules present in
mature neutrophils. Primary or azurophilic granules, which
are first to develop during granulopoiesis, contain myelo-
peroxidase (MPO) and a variety of proteolytic enzymes
(cathepsins, proteinase-3, and elastase), antimicrobial
defensins, and bactericidal/permeability-increasing protein
[73, 117–121]. These microbicidal granules are considered
unique from lysosomes, in that they lack traditional
lysosomal membrane markers and traffic as regulated
secretory granules [122–125]. The other major type of
granules present are secondary or specific granules, which
mature late during differentiation, and contain a number of
functionally important membrane proteins including flavo-
cytochrome b558, lactoferrin, collagenase, as well as
receptors for chemotactic peptides, cytokines, opsonins,
adhesion proteins, and extracellular matrix proteins [73,
117, 126–136]. Upon maturation, neutrophils are released
into the bloodstream where they circulate for ∼10–24 h
before migrating into tissue where they may function for an
additional 1–2 days before undergoing apoptosis and being
cleared by macrophages [73–75, 103, 104, 137, 138].
Normal neutrophil turnover in an average adult is on the
order of 10
11 cells per day [75]. In addition to maintaining
steady-state levels of circulating neutrophils, the hemato-
poietic system has the remarkable ability to drive “emer-
gency” granulopoiesis in response to the increased demand
of infection, expanding the pool of neutrophils in circula-
tion when necessary [139, 140].
Neutrophil recruitment
A dynamic portion of circulating neutrophils roll along
the walls of postcapillary venules, via transient inter-
actions with endothelial cells, surveying connective
tissue, mucosal membranes, skeletal muscle, and lym-
phatic organs for signs of tissue damage, inflammation,
or invading microorganisms [141–143]( F i g .1). This
dynamic pool of marginating cells searches for the
presence of host- and/or pathogen-derived chemotactic
signals or chemoattractants. In response to damage or the
presence of invading pathogens, a variety of host cells
such as monocytes, macrophages, mast cells, fibroblasts,
keratinocytes, endothelial and epithelial cells produce and
secrete potent inflammatory mediators and neutrophil
chemoattractants. These mediators include interleukin-
8 (IL-8, CXCL8), GROα (CXCL1), granulocyte chemo-
tactic protein 2 (GCP2, CXCL6), and leukotriene B4
(LTB4), which bind and engage specific surface receptors
on surveying neutrophils. These signals direct neutrophil
chemotactic movement out of intravascular circulation to
sites of damage or infection within tissues, resulting in a
rapid influx and accumulation of neutrophils. S. aureus
surface components such as lipoteichoic acid (LTA) or
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such as toxic shock syndrome toxin (TSST)-1, staphylo-
coccal enterotoxin A, and staphylococcal enterotoxin B
have been shown to elicit IL-8 production by monocytes,
epithelial cells, and endothelial cells [144–147]. Addition-
ally, CD4+ T-cells stimulated with S. aureus capsular
polysaccharide produce cytokines that recruit neutrophils to
sites of infection, demonstrating the range of cell types that
play a role in the recruitment of neutrophils [148, 149]. S.
aureus surface components, primarily peptidoglycan (PGN),
have also been shown to activate the complement cascade,
inducing production of the complement cascade component
C5a, another potent neutrophil chemotactic molecule [150].
Bacterial-derived products such as N-formyl peptides or the
phenol-soluble modulins (PSMs) produced by S. aureus
have the demonstrated ability to recruit neutrophils directly
[150–152].
Manyneutrophilchemotacticmoleculesalsoactaspriming
agents, serving to enhance neutrophil responses to a second
stimulus. Neutrophil priming, first described in the early
1980s,isclassicallydefinedastheabilityofaprimaryagonist,
typically at sub-stimulatory concentrations, to enhance the
production of superoxide in response to a second stimulus
[153]. Since then, many studies have expanded on the
original definition, going on to demonstrate that the priming
process occurs on almost all levels of neutrophil function,
including the enhancement of adhesion, phagocytosis,
cytokine secretion, leukotriene synthesis, degranulation, and
oxidative and non-oxidative microbicidal activities [154]. It
is thought that priming prepares neutrophils for maximal
Fig. 1 Neutrophil emigration from vascular space to site of infection
followed by phagocytosis and microbial killing. Marginating neutro-
phils survey post-capillary venules for signs of inflammation or
invading microorganisms, undergoing transient tethering interactions
with endothelial cells that facilitate neutrophil rolling along the
endothelial wall and allow neutrophils to search for host- and/or
microbe-derived chemotactic signals. Chemotactic molecules diffus-
ing from the site of infection and into the bloodstream bind specific
receptors on the neutrophil surface, arresting the rolling process and
inducing firm adherence to the endothelial wall. Firm adherence
subsequently leads to neutrophil transmigration through the endothe-
lial wall into the tissue, a process known as extravasation. Once in the
tissue, primed neutrophils chemotactically migrate to the site of
infection where they recognize and phagocytose invading micro-
organisms. Within the phagosome of the activated neutrophil,
microbes are destroyed by NADPH oxidase-derived reactive oxygen
species and antimicrobial proteins released upon granule fusion with
the phagosome (degranulation). See text for details. CR complement
receptor, FcR Fc receptor, MPO myeloperoxidase
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efficient clearance of such invaders. Corroborating evidence
to date demonstrates that the more responsive state of the
neutrophil is attributable to (a) partial assembly of the
NADPH oxidase, (b) reorganization of the plasma membrane
and redistribution of signaling molecules into lipid rafts, (c)
modulation of intracellular signaling intermediates, (d) mobi-
lization of secretory vesicles and enrichment of specific
surface receptors (CD11b/CD18), (e) cytokine secretion, and
(f) transcriptional regulation of several gene families [70].
Although priming leads to observable phenotypic differ-
ences, it remains distinct from neutrophil activation in that it
triggers neither release of azurophilic granules nor produc-
tion of superoxide [13, 153, 155]. Neutrophil priming is
induced by many host-derived factors, including cytokines,
chemokines, growth factors, lipid-derived signaling mole-
cules, as well as by physical cell–cell contact and adhesion
[154]. Many bacterial-derived factors also induce neutrophil
priming [154]. Some bacterial-derived products, such as
S. aureus LTA, are agonists for Toll-like receptors (TLRs),
which play a critical role in pathogen-mediated neutrophil
priming and pathogen recognition (discussed below).
Upon recognition of chemotactic signals and/or neutro-
phil priming, neutrophils exit peripheral circulation by
transmigration across the endothelial wall, a process known
as extravasation (Fig. 1). The process of extravasation
begins by tethering of neutrophils to endothelial cells,
transient interactions that facilitate rolling of surveying
neutrophils along the endothelial wall. Tethering interac-
tions are mediated by a family of C-type lectin glycopro-
teins known as selectins, which are upregulated on the
surface of cytokine-activated endothelial cells (E- and P-
selectin), activated platelets (P-selectin), and primed neu-
trophils (L-selectin, CD62) [141, 156]. Selectins expressed
on the surface of endothelial cells and neutrophils interact
with their respective carbohydrate ligands on the opposing
cell surface, resulting in initial tethering and subsequent
rolling of neutrophils along the endothelial wall [157].
Rolling is arrested by integrin-dependent interactions via
leukocyte adhesion molecules such as CD11a/CD18 (LFA-
1) and CD11b/CD18 (Mac-1), resulting in firm neutrophil
adhesion [158, 159]. Transmigration, facilitated by several
neutrophil surface molecules including CD31 (PECAM1),
CD54 (ICAM1), CD44, and CD47, may then proceed
between or through endothelial cells into tissues [160–164].
Following extravasation into tissues, polarized neutrophils
proceed to the site of infection by chemotaxis.
Pathogen recognition and phagocytosis
Once at the site of infection, the real work for neutrophils
begins, as they bind and ingest invading microorganisms by
a process known as phagocytosis, a critical first step in
removal of bacteria during infection. Neutrophils recognize
numerous surface-bound and freely secreted bacterial
products such as PGN, lipoproteins, LTA, lipopolysaccha-
ride, CpG-containing DNA, and flagellin. Such conserved
bacterial products are generally known as pathogen-
associated molecular patterns (PAMPs) and are recognized
directly by pattern recognition receptors (PRRs) expressed
on the surface of the neutrophil. Engagement of such
receptors activates signal transduction pathways that pro-
long cell survival, facilitate adhesion and phagocytosis,
induce release of cytokines and chemokines, elicit degran-
ulation, and promote reactive oxygen species (ROS)
production and release, ultimately contributing to micro-
bicidal activity [154]. The importance of PRRs in host
defense is perhaps exemplified by the enhanced suscepti-
bility of TLR2 deficient mice to infection by S. aureus
compared with wild-type mice [165]. Although many
chemoattractant molecules and TLR ligands have the ability
to elicit degranulation and ROS production, neutrophil
activation generally requires concentrations of ligand/
stimulus higher than that required for priming and
chemotaxis. Thus, activation is likely delayed until neu-
trophils reach sites of infection where concentrations of
stimulatory ligands are highest.
NOD-like receptors are PRRs located in the cell
cytoplasm rather than the plasma membrane or mem-
branes of granules. These proteins serve to detect
intracellular microbial components and respond similarly
to other PRRs by inducing downstream signaling cas-
cades involved in mediating inflammatory response and
neutrophil function [166]. For example, NOD2 senses
muramyl dipeptide derived from S. aureus PGN and
subsequently promotes transcription of NF-κB target genes
in the nucleus [166]. The collectins are a family of
secreted, soluble C-type lectins such as mannan-binding
lectin (MBL). Collectins are yet another type of PRR and
bind and recognize carbohydrate moieties on the surface of
invading microorganisms. These molecules enhance rec-
ognition by surface receptors on neutrophils (opsonization
via the lectin pathway of complement activation), activate
other PRRs, facilitate efficient phagocytosis, and elicit
release of cytokines and production of ROS [167–169].
Peptidoglycan recognition protein (PGRP) is a secreted
host protein that binds PGN and Gram-positive bacteria
[170, 171]. An isoform known as PGRP-short is produced
by neutrophils and contributes directly to bactericidal
activity rather than directing downstream signaling
responses [172].
Although many PRRs such as TLRs enhance binding
and recognition of microbes, there is little evidence to date
demonstrating that these receptors induce phagocytosis
directly, suggesting that PRRs may act as co-receptors
[173]. That said, there are exceptions to this idea. For
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on fungi and promotes phagocytosis and subsequent
neutrophil activation, ultimately killing ingested fungi
[174]. Unlike the unique phagocytic uptake induced by
dectin-1, phagocytosis of most microorganisms is promoted
or at least markedly enhanced by opsonization with serum
host factors, such as specific antibody, complement, and/or
MBL (generally fungi) [175]. For this purpose, neutrophils
express multiple antibody-Fc and serum complement
receptors, including CD16 (FcγIIIb, low affinity IgG
receptor) [176, 177], CD23 (FcεRI, IgE receptor) [178],
CD32 (FcγRIIa, low affinity IgG receptor) [179], CD64
(FcγRI, IgG receptor) [70], CD89 (FcαR, IgA receptor)
[180], CIqR [181], CD35 (CR1) [182, 183], CD11b/CD18
(CR3) [184, 185], and CD11c/CD18 (CR4) [186]. Activa-
tion of complement facilitates the deposition of comple-
ment components C3b, iC3b, and Clq on the surface of
invading microorganisms [70], and serum complement is
fixed readily on the surface of antibody-coated microbes.
Taken together, the combined action of PRRs, and
complement and antibody receptors maximizes recognition
and phagocytosis of invading microorganisms (Fig. 1).
The process of phagocytosis itself occurs independent
of clathrin, relying on regulation of actin polymerization
early in uptake and during formation of the nascent
phagosome [187]. The phagosome serves to restrict
nutrient sources and provides the neutrophil an isolated
compartment that may be made replete with an array of
toxic, microbicidal agents. Phagosomal maturation is a
stepwise process involving fusion of neutrophil secretory
vesicles and granules with the phagosome, which serves to
modify phagosomal membrane composition, and contents
and environment of the lumen [187]. This process also
enriches the phagosome with transmembrane components
of the NADPH oxidase, which in turn serve as the nidus
for assembly of the enzyme complex. Neutrophils have
remarkable phagocytic capacity, and for example, are able
to ingest more than nine yeast particles measuring 2×
3 μm, themselves having a diameter of only ∼10 μm
[188].
The process of neutrophil phagocytosis triggers synthe-
sis of a number of immunomodulatory factors [102, 189–
191]. Production of these factors by neutrophils recruits
additional neutrophils, modulates subsequent neutrophil
responses, and coordinates early responses of other cells
types such as monocytes, macrophages, dendritic cells, and
lymphocytes, thereby providing an important link between
innate and acquired immune responses. Additionally,
phagocytosis has been shown to accelerate programmed
cell death (apoptosis) of neutrophils, a process known as
phagocytosis-induced cell death (PICD) [102]. The phe-
nomenon of PICD is now considered a final stage of
neutrophil differentiation for activated cells and appears
critical to the resolution of the inflammatory response [101,
154]. This phenomenon will be discussed further below.
Neutrophil microbicidal activity
Neutrophils employ numerous oxygen-dependent and
oxygen-independent strategies to concertedly destroy in-
vading microbes. Phagocytosis is accompanied by the
generation of microbicidal ROS (oxygen-dependent) and
fusion of cytoplasmic granules with microbe-containing
phagosomes (degranulation). Degranulation enriches the
phagosome lumen with antimicrobial peptides and pro-
teases (oxygen-independent process), which in combination
with ROS create an environment non-conducive to survival
of the ingested microbe(s) (Fig. 1).
In the most classical sense, neutrophil activation is
intimately linked with the production of superoxide and
other secondarily derived ROS, an oxygen-dependent
process known as the oxidative or respiratory burst [192].
High levels of superoxide are generated upon full assembly
of the multi-subunit NADPH-dependent oxidase in both the
plasma- and phagosomal membranes. The active enzyme
complex is comprised of an integral membrane component,
flavocytochrome b558 (a heterodimer of gp91phox and
p22phox), that acts as the catalytic core of the complex
and is the electron transferase, and p40phox, p47phox,
p67phox, Rac2, and Rap1A, that act as cofactors for
oxidase activity [70, 192, 154]. In unstimulated neutrophils,
these components are segregated into membrane (flavocy-
tochrome b558 and Rap1A) and cytosolic (p40phox,
p47phox, p67phox) compartments. Upon activation, cyto-
solic components translocate rapidly to plasma and/or
phagosomal membranes [193–196]. The NADPH oxidase
transfers electrons from cytosolic NADPH to molecular
oxygen outside of the cell or within the phagosomal
compartment, thereby producing superoxide. Although
superoxide is thought to have limited direct microbicidal
capacity, the molecule is used to generate secondarily
derived ROS such as hypochlorous acid, hydroxyl radical,
chloramines, and singlet oxygen, all effective microbicides
[197–200]. The ability of neutrophils to produce large
amounts of superoxide relies on continued function of the
NADPH oxidase, a process that requires rapid charge
compensation and pH regulation in the phagosomal compart-
ment[201, 202]. Oxidase assembly and activity is modulated
by post-translational modifications of subunits (phosphory-
lation of p47phox)[ 203], interaction of subunits with lipid
signaling molecules (interaction of p40phox with phosphoi-
nositides) [204–206], and protein–protein interactions (e.g.,
SH3 domains present in p47phox,p 6 7 phox,p 2 2 phox)[ 207,
208]. The production of ROS derived from the NADPH
oxidase is critical to host defense against invading micro-
organisms, as exemplified by chronic granulomatous disease
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NADPH oxidase [209]. Patients with such defects suffer
from recurrent bacterial and fungal infections, including
infections caused by S. aureus [209].
The intricacy of concerted microbicidal efforts made
by the neutrophil is evident by the augmentation of the
oxygen-dependent microbicidal activity by MPO, an
abundant hemeprotein stored within azurophilic granules
[200]. In the phagosome, MPO catalyzes a reaction with
chloride and hydrogen peroxide to produce hypochlorous
acid, a potent oxidizing agent and microbicide, as well as
secondary products such as chloramines, hydroxyl radical,
and singlet oxygen [200]. The overall microbicidal
contribution of the MPO–halide system has been debated,
as patients with hereditary MPO-deficiency generally lack
any increased susceptibility to infection, suggesting that
ROS generated by NADPH oxidase and microbicidal
activity of granule proteins may be sufficient to compen-
sate for a lack of the MPO–halide system under certain
conditions [200, 210]. A redundancy in function of the
NADPH oxidase and the MPO–halide system was pro-
posed by Rosen and Klebanoff [211]. On the other hand,
neutrophil cytoplasts, which retain a respiratory burst but
lack MPO, are unable to kill ingested S. aureus unless
they are coated with MPO [212]. Furthermore, pharmaco-
logic inhibition of MPO leads to a decreased ability of
neutrophils to kill bacteria [213]. Neutrophils from MPO-
deficient patients do retain microbicidal activity against
several bacterial pathogens, although at a lower level
compared to neutrophils from normal donors, implying a
sub-maximal response [214]. Together, augmentation of
the NADPH oxidase by MPO facilitates a most efficient
response against invading microorganisms, while any
redundancy in function further demonstrates the importance
of the innate immune response.
Often overlooked in the past, oxygen-independent
killing mechanisms make a major contribution to the
unique microbicidal capacity of neutrophils. Evidence of
the importance of these mechanisms lies in the ability of
neutrophils to kill certain organisms under anaerobic
(oxygen limiting) conditions, wherein oxygen-dependent
generation of ROS does not occur [70]. Oxygen-
independent microbicidal agents include neutrophil antimi-
crobial peptides (AMPs) and antimicrobial proteins such as
α-defensins, cathelicidins, azurocidin, cathepsins, lactofer-
rin, lysozyme, proteinase-3, and elastase [70, 215]. These
agents are delivered by the regulated mobilization and
targeted fusion of cytoplasmic granules with either plasma
membrane (exocytosis) and/or phagosomal membranes
(degranulation) [216]. Regulation of mobilization and
targeting is incompletely defined, but in part involves (a)
regulation of actin/cytoskeletal rearrangement, (b) calcium-
and/or ceramide-mediated signal transduction, and (c)
soluble N-ehtylmaleimide sensitive factor attaching proteins
(SNAPs) and SNAP receptors (t-SNAREs) [70, 154].
Azurophilic (primary) and specific (secondary) granules
are differentially targeted, owing to differences in cargo
carried by each class of granule [70, 215]. Azurophilic
granules containing a variety of pore-forming peptides (α-
defensins), proteases (proteinase-3, elastase), and other
cytotoxic molecules (azurocidin, lysozyme, MPO), are
targeted primarily to the phagosome, exposing ingested
microbes to high concentrations of antimicrobial agents
[215]. Specific (secondary) granules containing integral
membrane components of the NADPH oxidase (flavocyto-
chrome b558) as well as some pore-forming peptides
(cathelicidins) and cytotoxic molecules (lysozyme) are
targeted to both the plasma membrane and the phag-
osome, serving the additional function of enriching the
plasma membrane with critical components of the
NADPH oxidase and surface molecules/receptors impor-
tant for neutrophil response (integrins, chemotactic and
opsonic receptors) [70, 215]. Specific granules also
contain lactoferrin, an iron-binding protein which utilizes
an additional, unique strategy against ingested microbes.
Lactoferrin sequesters iron needed for microbial growth
and also modulates Fenton-derived production of hydroxyl
radical [217, 218]. A similar strategy has been described
for neutrophil calprotectin (S100A8/A9), which inhibits
growth of S. aureus by sequestering nutrient Mn
2+ and
Zn
2+ within abscesses [219]. The majority of microbicidal
activity takes place within mature phagosomes. However
secreted, extracellular molecules, namely the group IIA
phospholipase A2 (gIIA-PLA2), have been shown to act
synergistically with neutrophil NADPH oxidase to promote
digestion of S. aureus phospholipids, demonstrating collab-
oration between oxygen-dependent and oxygen-independent
killing mechanisms [220].
In addition to ROS production and degranulation, a third
neutrophil microbicidal mechanism has recently been
proposed. Novel structures known as neutrophil extracellu-
lar traps (NETs), which contain decondensed chromatin,
bound histones, azurophilic granule proteins, and cytosolic
proteins, have a demonstrated capacity to bind to and kill a
variety of pathogens including S. aureus [221]. Extrusion of
such structures by neutrophils is predicted to limit microbial
spread and dissemination, while enhancing effective con-
centrations of extruded microbicidal agents, thereby pro-
moting synergistic killing of attached microorganisms
[222]. It is debated whether extrusion of such structures is
to be classified as a novel form of cell death or if these
structures are extruded from live, intact cells. The phenom-
enon of NETosis has also been observed in other
granulocyte cell types including mast cells and eosinophils
[222, 223]. The molecular basis of NET formation is yet
poorly understood, although the process is directly linked to
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functional NADPH oxidase, are unable to form NETs
[224]. In vivo demonstrations of such structures have been
provided by a limited number of human infectious and non-
infectious diseases, as well as several animal infection
models [222, 223]. It is not clear whether NETs alter the
normal course of the inflammatory response or perhaps
exacerbate inflammation. It has even been proposed that
formation of NETs may contribute to autoimmune disorders
[222]. The role of NETs in the innate immune response and
our understanding of the mechanisms underlying this
process remain incompletely defined and will require
further research.
Neutrophil apoptosis and the resolution of inflammation
Turnover of immune cells is essential for maintenance and
homeostasis of both innate and acquired immune systems,
ensuring that cells working “out in the field” have sufficient
functional capacity. Turnover is accomplished universally
by the process of apoptosis or programmed cell death,
which facilitates efficient, non-phlogistic removal of senes-
cent or effete cells of all types [225, 226]. This process
becomes increasingly critical for cells that carry high
cytotoxic capacity and pro-inflammatory potential, such as
neutrophils. Additionally, neutrophils are the most numer-
ous leukocytes in humans, have a rapid rate of turnover,
and critically function as first responders, further under-
scoring the importance of regulated, efficient removal of
such cells in a manner that serves to prevent unnecessary
host tissue damage and inflammation. Following apoptosis,
which maintains neutrophil membrane integrity and pre-
vents release of cytotoxic neutrophil contents, apoptotic
neutrophils are recognized and ingested by macrophages
without pro-inflammatory consequence, completing the
turnover cycle. In the absence of stimulation, senescent
neutrophils undergo spontaneous or constitutive apoptosis,
a process initiated by signaling from within the cell,
resulting in caspase activation and eventual removal by
macrophages [227]. This intrinsic ability to undergo
apoptosis is essential for maintaining appropriate cell
numbers in circulation [228]. In the context of infection,
where neutrophils are recruited to sites of infection,
phagocytosisandsubsequentneutrophilactivationsignificant-
ly accelerates apoptosis, a process known as phagocytosis-
inducedcelldeath(PICD)nowthoughttoplayacentralrolein
resolution of the inflammatory response [106, 229, 230]
(Fig. 2).
At the onset of infection, an influx of neutrophils to
respective sites within tissues isdriven by detection of a series
of host- and/or bacterial-derived immunomodulatory factors
that influence chemotactic movement and prime neutrophils
for enhanced function. Many of these early pro-inflammatory
signals have the additional ability to delay spontaneous
neutrophil apoptosis, implying that increased survival of
neutrophils is desirable early in the inflammatory
process, perhaps promoting efficient pathogen recogni-
tion and removal [226, 231]. Additionally, phagocytic
uptake of invading microorganisms induces a neutrophil-
mediated acute pro-inflammatory response, as evidenced
in part by increased levels of transcripts involved in the
acute inflammatory response [101]. More recently, it has
become clear that phagocytosis of numerous pathogens,
including S. aureus, significantly accelerates neutrophil
apoptosis/PICD [232, 233]. Apoptosis ultimately leads to
an overall decreasein cellular functions including a decreased
ability to produce ROS, phagocytose, secrete cytokines,
adhere, and chemotax [190, 234]. Concomitant to rapid
induction of apoptosis is an accompanied downregulation of
neutrophil pro-inflammatory capacity, illustrating the fine
balance of signals required for effectively dealing with
invaders and resolving acute inflammation [102, 190]. As
apoptosis progresses, neutrophils undergo important cell
surface changes including transposition of phosphatidylser-
ine, oxidized lipids, and carbohydrate moieties to the
external surface, marking apoptotic neutrophils for recogni-
tion by surface receptors on macrophages [235]. Recognition
by macrophages leads subsequently to ingestion (efferocy-
tosis) and non-phlogistic removal of apoptotic cells, as well
as release of anti-inflammatory molecules, such as TGF-β
and IL-10 [103, 236–238]( F i g .2). The importance of this
removal process is highlighted by the redundancy of
recognition receptors described for macrophages [101]. Mice
lacking the macrophage receptor for phosphatidylserine
accumulate apoptotic cells in the lung and brain, and develop
autoimmune disorders [239, 240]. Thus, it is clear that
neutrophil apoptosis plays a central role in desired resolution
of the acute inflammatory response.
S. aureus immune evasion mechanisms
Many pathogens, including S. aureus, have a long history
of interaction with the human innate immune system.
Therefore, it is not surprising that many pathogens have
evolved mechanisms to evade and combat this important
f r o n tl i n eo fh o s td e f e n s e .S. aureus has evolved an
abundant repertoire of factors aimed at evasion of the
innate system, including host defense strategies utilized by
neutrophils. There exists significant redundancy in the
numerous mechanisms employed by S. aureus against the
innate immune system, reflecting the importance of such
defenses and their role in the outcome of infection. S.
aureus factors characterized to date include those that
prevent recognition and binding of the pathogen by
neutrophils, as well as those that provide protection against
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passive defense mechanisms, S. aureus secretes several
cytotoxic molecules that have the ability to damage
immune cells [10].
S. aureus attempts to minimize or inhibit recognition by
the host by hiding and/or modifying the bacterial surface.
This is afforded by production of exopolymers such as
capsular polysaccharide forming the bacterial capsule and/
Fig. 2 S. aureus immune evasion mechanisms and possible outcomes
of bacteria–neutrophil interaction. A Immune evasion by S. aureus
includes strategies that serve to prevent recognition, inhibit chemotaxis,
moderate ROS, protect against AMPs, and directly damage immune
cells. B Phagocytic uptake of bacteria triggers production of ROS and
degranulation, working collectively to kill ingested bacteria, after which
neutrophils undergo apoptosis to be removed by macrophages and
promote healthy resolution of infection. Alternatively, bacterial patho-
gens can alter normal neutrophil turnover, promoting either a delay in
neutrophil apoptosis or an accelerated neutrophil lysis. Alteration of
normal neutrophil turnover facilitates pathogen survival and promotion
of disease. APS antimicrobial peptide-sensing system, Aur aureolysin,
CHIPS chemotaxis inhibitory protein of S. aureus, CP capsular
polysaccharide, Hla α-toxin, HlgABC γ-hemolysin, LukGH LukF-G
and LukS-H, MprF multiple peptide resistance factor, PIA polysaccha-
ride intercellular adhesion, PSMs phenol-soluble modulins, PVL
Panton–Valentine leukocidin, Sbi second binding protein of immuno-
globulin, SCIN staphylococcal inhibitor of complement, SOD superox-
ide dismutase, TSST toxic shock syndrome toxin, VraFG vancomycin-
resistant-associated gene, ABC transporter
246 Semin Immunopathol (2012) 34:237–259or polysaccharide intercellular adhesion, a unique extracel-
lular matrix biofilm component that serves to modify the
typical negative charge of the bacterial outer surface [241–
244]. Additionally, the well-known protein A, which binds
the Fc region of IgG, lends the ability to coat the bacterial
surface with non-specific antibodies (in the wrong orienta-
tion), providing immunologic disguise and potentially
disrupting opsonization and phagocytic uptake [245, 246].
Chemotaxis inhibitory protein of S. aureus and staphylo-
coccal complement inhibitor block receptor mediated
recognition of N-formyl peptides produced by bacteria
and complement-mediated uptake, respectively [247, 248].
Curiously, despite the numerous mechanisms employed by
S. aureus to inhibit binding and phagocytosis by neutro-
phils, these phagocytes rapidly take up the pathogen.
Protection against host oxygen-dependent microbicidal
killing mechanisms is in part provided by catalase and
superoxide dismutase, which eliminate harmful ROS
produced within the phagosome following ingestion [13].
Staphyloxanthin is a golden pigment produced by S. aureus
and has also been shown to play a protective role against
ROS [249]. Mechanisms also exist for bacterial defense
against oxygen-independent killing mechanisms, including
thosemediatedbyAMPs.Inadditiontoreleasingnon-specific
proteases [250], S. aureus senses the presence of AMPs via a
three-component gene-regulatory system, which regulates
downstream bacterial responses including the D-alanylation
of teichoic acids and incorporation of lysyl-phosphatidyl
glycerol in the plasma membrane, thereby decreasing overall
negative charge of the bacterial surface [251–254]. These
surface modifications reduce the efficiency of the binding of
cationic AMPs to the bacterial surface. Furthermore, the
VraFG transporter is responsible for the removal of AMPs
from the cytoplasm or plasma membrane [251, 252]. In
additiontotheseratherpassivedefensemechanisms,S. aureus
produces a number of toxins that directly attack white and
red blood cells. Such toxins include a family of leukocidins,
α-toxin (α-hemolysin), and the recently described PSMs.
These molecules have the ability to form pores in target cell
membranes [152, 255]. Lastly, several types of secreted S.
aureus toxins are also classified as superantigens, taking the
strategy of overstimulating the immune response to potentiate
undesired responses and cause disease [256, 257]. Examples
of superantigenic toxins include TSST and staphylococcal
enterotoxins [257].
It is evident that apoptosis plays a major role in the
resolution of the acute inflammatory response, likely
having an impact on the outcome of disease. That being
said, some pathogens have also devised means to modulate
normal turnover and apoptosis of neutrophils, leading to
alterations in the desired resolution of infection [226]
(Fig. 2). Although the short life-span of neutrophils is not
conducive to the long-term survival strategies employed by
many intracellular pathogens, Anaplasma phagocytophi-
lum, the causative agent of human granulocytic anaplas-
mosis, has the ability to delay neutrophil apoptosis,
supporting replication and survival of the pathogen within
an endosomal compartment [189, 226, 258]. On the other
hand, S. aureus, especially CA-MRSA strains, have the
remarkable ability to induce rapid lysis of neutrophils and/
or accelerate PICD to the point of secondary lysis,
potentiating undesired release of neutrophil contents and
pathogen survival [71, 72, 102, 226]. In either case,
modulation of the normal turnover process results in
pathogen survival, promotion of pathogenesis, and likely
dissemination and disease (Fig. 2).
Community MRSA virulence and evasion of killing
by neutrophils
The increased virulence of CA-MRSA strains was initially
inferred from (a) the ability of these strains to cause disease
in otherwise healthy individuals, (b) the ability of these
strains to cause unusually severe disease, and (c) their
ability to spread rapidly among groups of individuals.
Corroborating the epidemiologic data, experimental data
have demonstrated conclusively that CA-MRSA strains are
more virulent than representative HA-MRSA strains in
animal models of infection [71, 72]. Increased virulence is
attributed largely to an enhanced capacity of CA-MRSA
strains to resist killing by neutrophils, compared to HA-
MRSA strains [72]. Survival of CA-MRSA strains in in
vitro assays with human neutrophils leads to rapid lysis of
these host cells, and release and ultimate growth of bacteria
[72, 259]. This follows with the idea that increased
virulence lies, at least in part, in the enhanced ability to
alter normal neutrophil function and turnover.
Early distinction of CA-MRSA strains from traditional
HA-MRSA strains, which included differences in PFGE
typing and antibiotic resistance profiles, suggested that CA-
MRSA strains were not merely hospital strains that had
escaped into the community. Therefore, efforts to under-
stand the molecular basis of the enhanced virulence of CA-
MRSA strains have since focused on identifying additional
genotypic and phenotypic differences between CA-MRSA
and traditional HA-MRSA strains. Although significant
progress has been made in understanding components that
contribute to the success of CA-MRSA, a complete
understanding is complicated by the multi-factorial ap-
proach to virulence that is intrinsic to S. aureus. That is, no
single virulence factor contributes exclusively, making it
difficult to determine contributions made by individual
components that have overlapping or redundant functions.
Despite this obstacle, several S. aureus virulence determi-
nants are implicated in the success of CA-MRSA.
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is a widely studied pore-forming toxin capable of
destroying a variety of host cells, including epithelial
cells, erythrocytes, fibroblasts, monocytes, macrophages,
and lymphocytes (but not neutrophils), and has long been
considered a major virulence determinant of S. aureus
[260, 261]. Although it is ubiquitous among clinical
isolates, recent studies have clearly demonstrated a
primary role for α-toxin in experimental CA-MRSA
infections. CA-MRSA strains lacking α-toxin were avir-
ulent in a murine pneumonia model of infection compared
with isogenic wild-type strains, and active and passive
immunization against α-toxin provided animals protection
f r o md e a t hi nt h es a m em o d e l[ 262, 263]. Mechanistically,
α-toxin elicits a host chemokine response in the murine
pneumonia model, promoting an influx of neutrophils
thought to be largely responsible for lung injury during
infection [264]. Importantly, the amount of α-toxin
produced by CA-MRSA in vitro correlates with the
severity of lung disease observed in such animal models
[262, 265, 266]. The role of α-toxin has also been
demonstrated in murine and rabbit models of CA-MRSA
skin infection, providing further evidence that α-toxin
plays a major role in CA-MRSA disease [267, 268].
α-Type phenol-soluble modulins (α-PSMs) are a subset
of recently reported PSMs [152]. These molecules are
surfactant-like, amphipathic, α-helical peptides (∼20–25 aa
in length) with limited homology to PSMs produced in
other staphylococcal species including Staphylococcus
epidermidis [152]. The α-PSMs are ubiquitous to all
sequenced S. aureus strains, have the ability to induce
neutrophil chemotaxis and cytokine release through a
specific receptor-mediated process, and also have the ability
to lyse neutrophils, erythrocytes, and monocytes via a
receptor-independent process [152]. Isogenic mutant CA-
MRSA strains that lack α-PSMs have significantly reduced
virulence in murine bacteremia and skin infection models
compared to wild-type parental strains, indicating they are
major determinants of CA-MRSA virulence [152]. Notably,
in vitro production of α-PSMs by CA-MRSA strains is
significantly higher than that of prominent HA-MRSA
strains. Additionally, overexpression of α-PSMs in a
representative HA-MRSA strain increases cytotoxic capacity
of culture supernatants to a level comparable to that observed
with CA-MRSA culture supernatants, indicating that the
difference in cytolytic capacity between CA-MRSA and
HA-MRSA strains is largely due to differential production
of α-PSMs [152]. However, the contribution of α-PSMs to
neutrophil lysis following phagocytosis remains to be
determined. Production of α-PSMs is regulated in part by
the accessory gene regulator (agr), a well-known, global
regulatory/quorum sensing system. α-Toxin and α-PSMs are
both encoded in the core genome, as opposed to mobile
genetic elements (MGEs), which encode many other S.
aureus virulence molecules. Recent analysis of gene expres-
sion within subclones of S. aureus clonal complex 8 (defined
by MLST), including USA300 and other closely related
strains, revealed that USA300 has increased expression of
core-genome encoded virulence factors such as α-toxin and
α-PSMs, lending to the novel idea that enhanced virulence is
based largely on differential expression of core-genome
elements rather than strictly acquisition of MGEs [269].
Differential expression of core-genome determinants is likely
due to poorly understood rearrangements of gene regulatory
networks in these strains.
It is likely that the extraordinary success of CA-MRSA
also involves unique genetic factors that facilitate coloni-
zation and transmissibility. Although such factors may not
contribute directly to virulence, they may be important for
the overall burden of disease, as seen with the rapid
dissemination of CA-MRSA among groups of individuals.
One such factor is the type-I arginine catabolic mobile
element (ACME), an MGE unique to USA300, identified
by whole genome sequencing [270]. This 31-kb MGE is
physically linked to the SCCmec type IV element and may
have been acquired from S. epidermidis [67, 270]. ACME
encodes two gene clusters, one encoding a complete
arginine deiminase (arc) pathway, and the other an
oligopeptide permease operon. Arginine deiminase activity
produces ammonia and ATP and might facilitate coloniza-
tion by neutralizing the acidic environment found on skin
as well as producing an additional source of ATP [67]. In
addition, depletion of the arginine pool may serve to
prevent efficient production of nitric oxide, a key immune
molecule[271]. Oligopeptide permeases are usually involved
in peptide uptake as a nutrient source, although they are also
implicated in other functions such as quorum sensing,
chemotaxis, cell adhesion, and resistance to AMPs [270].
Experimental models of infection have demonstrated either
no impact or a limited impact of ACME on virulence [67,
272]. Although a function related to enhanced colonization
and/or persistence on human skin, leading to increased
transmissibility, has been inferred from the putative functions
of genes found within ACME, the physiologic function of
these gene clusters in the context of CA-MRSA pathogenesis
remains to be determined. This will require experimental
colonization models to directly assess any role ACME may
play in the colonization, persistence, and/or transmissibility
of CA-MRSA.
Panton–Valentine leukocidin (PVL) is a bi-component
cytolytic toxin encoded on a prophage acquired by
horizontal gene transfer [273]. PVL has the ability to prime
neutrophils, induce proinflammatory responses such as
cytokine release, and has long been known, at higher
concentrations, to lyse leukocytes by forming pores in
target-cell membranes [42, 274–279]. PVL genes are
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and the toxin is associated with S. aureus strains that cause
certain types of severe skin infections (e.g., furuncles and
carbuncles) and necrotizing pneumonia [42, 280–282]. It is
noteworthy that PVL was also present in the pandemic
phage-type 80/81 clone, which caused severe infections in
hospitals and the community in the 1950s and 1960s [283].
Therefore, elucidating the role for PVL (if any) in the
success of CA-MRSA has been of great interest and
remains a hotly debated topic in light of many experimental
studies, some of which are conflicting. Numerous animal
models of infection have been utilized to investigate PVL’s
contribution during CA-MRSA infections including mu-
rine, rat, rabbit, and non-human primate models of skin
infection, bacteremia, and pneumonia [11–13, 17]. Gener-
ally, findings from studies to date indicate that PVL makes
little or no unique contribution to the virulence of CA-
MRSA, but may contribute in specific contexts resulting in
severe diseases or syndromes [12, 71, 284–288]. Due to
that fact that PVL production is sensitive to environmental
conditions (e.g., growth media) and is strain dependent, as
well as the fact that the susceptibility of white blood cells to
PVL differs among mammalian species, it is not surprising
that conflicting findings have been reported [289, 290].
Recently Kobayashi et al. investigated the role of PVL in a
novel rabbit subcutaneous skin infection model, reporting
that a USA300 wild-type and isogenic lukS/F-PV deletion
strains produced similar abscesses, whereas deletion of
genes encoding other well-established virulence determi-
nants—α-toxin, α-PSMs, and Agr—decreased abscess
formation [267]. Concurrently, a rabbit intradermal skin
infection model was published using similar strains, but
these authors reported a role for PVL in pathogenesis of S.
aureus skin infection [291]. These seemingly contradictory
findings highlight the possibility that PVL functions in
specific experimental contexts, and emphasizes the need for
careful interpretation and comparison among experimental
models used. Taken together, evidence to date indicates that
PVL is not a major virulence determinant of CA-MRSA,
but is simply one of many S. aureus secreted molecules that
can contribute to infection.
A recent surface proteome study of USA300 identi-
fied an abundant, novel two-component leukotoxin,
LukGH, related to other two-component toxins of S.
aureus such as PVL [292]. LukGH is localized to the cell
s u r f a c ea n di ss e c r e t e di n t oc u lture medium. Importantly,
LukGH has potent cytolytic activity toward neutrophils,
acts synergistically with PVL to cause neutrophil lysis in
vitro, and is highly expressed during phagocytosis. These
results suggest LukGH contributes to USA300 virulence
[292]. Further investigation is required to demonstrate a
physiologic role for LukGH in the ability to cause
disease.
Neutrophil defects and S. aureus infections
Acquired and congenital defects of the immune system are
associated with an increased susceptibility to infectious
disease. Description of numerous primary immunodeficien-
cy diseases (PIDs), defined here as a genetically determined
disorder resulting in an enhanced susceptibility to infectious
disease, has served to bolster the importance of many
human immune functions, including the role of neutrophils
in defense against bacterial pathogens such as S. aureus
[209, 293–295]. PIDs are broadly classified based on their
underlying molecular defect and include deficiencies in
humoral immunity (B lymphocytes, antibodies), cell-
mediated immunity (T cell-mediated), combined humoral
and cell-mediated immunity, and non-specific host defense
(phagocytes, natural killer cells, complement pathway).
PIDs characteristically present in childhood with persistent,
recurrent, and difficult to treat infections. Importantly,
pathogen susceptibility patterns, sites of infection, and
complications of infection are known to vary according to
immune deficit, and are major considerations made during
diagnosis [293, 295]. Each class of primary immunodefi-
ciency has a characteristic set of infectious predispositions
that are often employed to guide initial diagnostic testing
[293]. Defects in T cell function are generally associated
with infections caused by viruses and Candida species,
whereas patients with primary phagocyte defects yield an
increased susceptibility to specific bacterial and fungal
infections [209]. In some cases, pathogen susceptibility
points to the specific disorder; susceptibility to intracellular
pathogens such as mycobacteria, Salmonella, and Listeria
is suggestive of a defect in the interferon-γ−interleukin-12
signaling axis [209], while infections caused by S. aureus
and Aspergillus species predominate among patients with
CGD [293].
Several PIDs have been described for a range of
underlying primary neutrophil defects, including functional
defects in neutrophil adhesion, chemotaxis, phagocytosis,
vesicle trafficking, NADPH oxidase assembly/function,
MPO deficiency, glucose/glycogen metabolism, signal
transduction, and granular defects [70]. Many of these
defects are closely associated with increased susceptibility
to S. aureus infections, and often result in life-threatening
and/or fatal complications. Severe congenital neutropenia
(SCN) is associated with mutations from two different
genes; mutation in HAX1, a mitochondrial protein thought
to have an anti-apoptotic role, is associated with an
autosomal dominant form of SCN, while mutation of
ELA2, the gene encoding elastase 2, is associated with an
autosomal recessive SCD resulting from endoplasmic
reticulum (ER) stress, unfolded protein response (UPR),
and apoptosis [70]. Infectious complications arising in SCN
patients include cellulitis, perirectal abscesses, peritonitis,
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tions caused by S. aureus and Pseudomonas aeruginosa
[209, 296]. Leukocyte adhesion deficiency types 1 and 2
(LAD1 and 2) are caused by defects in adhesion molecules
such as CD18 (β2 integrin; LAD1) or an inability to
fucosylate glycoproteins acting as ligands for E-selectins
(LAD2), respectively [209, 293, 295]. As a result of their
inability to make initial attachment, or adhere tightly to
endothelial cells, neutrophils are unable to egress from the
vasculature to sites of infection [209, 293]. Clinical
manifestations include delayed separation of the umbilical
cord, poor wound healing, recurrent skin and soft-tissue
infections, genital mucosa infections, intestinal and respi-
ratory tract infections, and severe periodontitis. Infecting
pathogens include S. aureus, Gram-negative enteric bacte-
ria, Candida species, and Aspergillus species [209].
Chédiak–Higashi syndrome is a disorder caused by muta-
tions that affect the lysosomal transport protein LYST, and
thus prevents normal phagolysosome formation and granule
fusion [209, 293, 295]. This syndrome is partly character-
ized by recurrent, severe S. aureus infections. Other
neutrophil disorders associated with S. aureus infections
include neutrophil-specific granule deficiency and hyper-IgE
syndrome (Job’ss y n d r o m e )[ 209, 293]. Importantly, some of
these neutrophil disorders may involve defects in regulation
of neutrophil apoptosis and/or turnover. Taken together,
neutrophil function plays a major role in clearance of
invading bacterial pathogens such as S. aureus.
Summary and outlook
S. aureus remains a major cause of human infections, and
the rise of highly virulent, drug-resistant strains has made
treatment increasingly difficult. As a result, the overall burden
of disease has increased within both the hospital and
community settings, emphasizing the need for alternative
therapeutic approaches. Although progress has been made
toward understanding mechanisms used by S. aureus to evade
innate host defenses, especially those involving neutrophils,
our knowledge in this area is incomplete. The ability of S.
aureus to evade primary host defenses plays a major role in
the outcome of infection, as evidenced by the enhanced ability
of CA-MRSA to evade and combat innate immunity and
ultimately destroy neutrophils. This process likely contributes
to the enhanced virulence of prominent CA-MRSA strains
and their capacity to cause severe disease in otherwise healthy
individuals. Therefore, a comprehensive understanding of the
interface between innate host defense and S. aureus is needed
to identify alternative therapeutic approaches. Underlying host
genetic factors are likely important determinants of suscepti-
bility to severe disease and must also be considered for
development of alternative treatments.
Renewed efforts—fueled by the rise of antibiotic-resistant
strains—to develop vaccines that promote opsonophagocyto-
sis of S. aureus have not been successful. The problem is
twofold. First, S. aureus opsonized in normal human serum is
readily phagocytosed by human neutrophils and there is no
need to improve efficiency of uptake, which is the primary
purpose of opsonophagocytic vaccines. Second, S. aureus,
especially CA-MRSA, causes lysis of neutrophils following
phagocytosis [297, 298]. This is a significant problem
because, as stated above, neutrophils are the most prominent
cellular defense against S. aureus infections. Ideally, a
therapeutic maneuver would enhance the killing capacity of
neutrophils after uptake of the pathogen or render S. aureus
incapable of defending itself against microbicides produced
by neutrophils. Novel approaches to target virulence as a
means of attenuating disease are underway and include
strategies such as passive immunization with antibodies
against main virulence determinants of S. aureus [299]. Some
potential targets have been provided by identification of
virulence determinants of CA-MRSA, including α-toxin
and α-PSMs. For example, passive immunization with
anti-α-toxin antibodies provides protection against lethal
pneumonia in a murine model of infection, demonstrating
the potential utility of such therapy as an adjunct to
antibiotic administration [263]. However, much functional
redundancy exists among the numerous S. aureus virulence
determinants, requiring a combinatorial therapeutic approach
that includes targeting the most important virulence determi-
nants. Therefore, elucidation of the contribution of host
factors, as well as the major bacterial virulence determinants,
to the development of severe disease is of major interest to
future research.
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